Abstract
Rheumatic disease patients often have both systemic and localized inflammatory processes. The result of this inflammation is tissue destruction and this translates into bone loss. Recent studies have highlighted the importance of systemic factors that either directly or indirectly activate receptor activator of nuclear factor-kB ligand (RANKL) dependent osteoclast activation and induce bone loss. In this article we will review the pathogenesis of inflammatory bone loss and explore the possible interventions to prevent it.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 675-679 |
| Number of pages | 5 |
| Journal | Lupus |
| Volume | 11 |
| Issue number | 10 |
| DOIs | |
| State | Published - 2002 |
| Externally published | Yes |
Fingerprint
Keywords
- Bone loss
- Rheumatology patients
ASJC Scopus subject areas
- Rheumatology
- Immunology
Cite this
Osteoporosis in the rheumatic disease patient. / Lane, Nancy E; Rehman, Q.
In: Lupus, Vol. 11, No. 10, 2002, p. 675-679.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Osteoporosis in the rheumatic disease patient
AU - Lane, Nancy E
AU - Rehman, Q.
PY - 2002
Y1 - 2002
N2 - Rheumatic disease patients often have both systemic and localized inflammatory processes. The result of this inflammation is tissue destruction and this translates into bone loss. Recent studies have highlighted the importance of systemic factors that either directly or indirectly activate receptor activator of nuclear factor-kB ligand (RANKL) dependent osteoclast activation and induce bone loss. In this article we will review the pathogenesis of inflammatory bone loss and explore the possible interventions to prevent it.
AB - Rheumatic disease patients often have both systemic and localized inflammatory processes. The result of this inflammation is tissue destruction and this translates into bone loss. Recent studies have highlighted the importance of systemic factors that either directly or indirectly activate receptor activator of nuclear factor-kB ligand (RANKL) dependent osteoclast activation and induce bone loss. In this article we will review the pathogenesis of inflammatory bone loss and explore the possible interventions to prevent it.
KW - Bone loss
KW - Rheumatology patients
UR - http://www.scopus.com/inward/record.url?scp=0036029872&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036029872&partnerID=8YFLogxK
U2 - 10.1191/0961203302lu261oa
DO - 10.1191/0961203302lu261oa
M3 - Article
VL - 11
SP - 675
EP - 679
JO - Lupus
JF - Lupus
SN - 0961-2033
IS - 10
ER -